TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04353245

Intervention type: OTHER
Intervention: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM
Description: Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.

Intervention type: OTHER
Intervention: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM
Description: Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
Study: NCT02236468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program (old)
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced-Homestead Food Production Program (old)
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WASH/malaria behavior change
Description: WASH/malaria behavior change communication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WASH/malaria behavior change
Description: WASH/malaria behavior change communication

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WASH/malaria behavior change
Description: WASH/malaria behavior change communication

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: LNS distribution
Description: Distribution of Nutributter (Fanga Degue) for children

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program (new)
Description: Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced-Homestead Food Production Program (new)
Description: Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
Study: NCT01914263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine induced killer cell
Description: The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
Study: NCT03958058

Intervention type: DRUG
Intervention: Anti-borrelial antibiotic therapy
Description: Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: OTHER
Intervention: No antibiotic.
Description: Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study: NCT00748345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin (drug)
Description: pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
Study: NCT00900666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A (BTX-A)
Description: 200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
Study: NCT04320017

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
Description: * 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide
Study: NCT04038489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg aspirin daily during AC-T chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Pill
Description: Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
Study: NCT01743495

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 home-based functional services sessions over 4 months.
Description: The program consists of up to 10 home-based functional services sessions over 4 months.
Study: NCT03430778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High end-tidal CO2
Description: maintaining of end-tidal CO2 with the range of 40-45 mmHg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low CO2 group
Description: maintaining of end-tidal CO2 with the range of 30-35 mmHg
Study: NCT00462007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo
Description: Oral 3-4 daily doses for 6 weeks
Study: NCT02444949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity modulated radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT03368365

Intervention type: DEVICE
Group type: OTHER
Intervention: Ventilotel ®
Description: Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
Study: NCT02544607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.5mg/kg over 40 minutes IV
Study: NCT06018948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.6
Description: Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.3
Description: Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
Study: NCT02544607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI technology will be used before and after ketamine for patients with depression
Study: NCT02912507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera enlighten laser
Description: high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
Study: NCT04163029

Intervention type: PROCEDURE
Intervention: Preoperative oral care
Description: tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
Study: NCT01966523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT00407186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin+capecitabine
Description: cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 45 Gy in 25 fracions (5 days/week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin+cisplatin+capecitabine
Description: 3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
Study: NCT02246959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process Incentive
Description: Daily sweepstake conditional on daily medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process Incentive
Description: Daily sweepstake conditional on daily medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome Incentive
Description: Incentives conditional on LDL cholesterol reduction
Study: NCT02912507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CynoSure PicoSure 755nm laser
Description: high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
Study: NCT02246959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome Incentive
Description: Incentives conditional on LDL cholesterol reduction
Study: NCT02140515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutropin alfa
Description: Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa and Lutropin alfa
Description: Administration of (rFSH) and (rLH)
Study: NCT01569594

Intervention type: DEVICE
Intervention: CorMatrix ECM for Carotid Repair
Description: Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
Study: NCT02471794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Health Planning Shared Medical Appointment
Description: The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
Study: NCT02807207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: pacritinib
Description: Treatment A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Placebo
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: moxifloxacin
Description: Treatment C
Study: NCT03721341

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Radiation
Description: Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy may be given as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy may be given as indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Immunotherapy may be given as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy may be given as indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: Hormones may be given as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormones
Description: Hormones may be given as indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Observation only is acceptable if this is the standard practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation only is acceptable if this is the standard practice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
Study: NCT04157777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineum massage with olive oil
Description: Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale.
Study: NCT03573843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention software
Description: All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
Study: NCT03910309

Intervention type: DEVICE
Intervention: TLIF with Titan TT/TO interbody cage
Description: fusion surgery
Study: NCT02940392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.
Study: NCT00616304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine hydrochloride
Description: Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
Study: NCT01030055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258 (dovitinib)
Description: bioavailability (anhydrate capsules) food (monohydrae capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258 (dovitinib)
Description: bioavailability (anhydrate capsules) food (monohydrae capsules)
Study: NCT04522453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based version of mental health Gap Action Program-Intervention Guide
Description: A paper-based guide for diagnosis and management of mental disorders in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital version of the mental health Gap Action Program-Intervention Guide
Description: A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
Study: NCT02058953

Intervention type: PROCEDURE
Intervention: Craniotomy scheduled
Description: Resection of affected brain tissue

Intervention type: PROCEDURE
Intervention: Collection for non-craniotomy
Description: CSF, Blood, biopsy
Study: NCT03326778

Intervention type: PROCEDURE
Intervention: AVR and CABG
Description: Combined AVR with CABG
Study: NCT02278926

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound measurements

Intervention type: OTHER
Intervention: Tapping and body inspection to define the area of insulin injection
Description: Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
Study: NCT02794766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin+SS
Description: Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S salivarius
Description: Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 gum each 12 hours for 10 days
Study: NCT03018899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Ultrasound guided two-segment paravertebral block
Study: NCT05127707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
Study: NCT03018899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: thoracic epidural anesthesia
Study: NCT01083823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental health telemetry (MHT)
Description: Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental health telemetry (MHT)
Description: Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.